Steve Byrne

Analyst: As Chemical Sector Takes A Hit, Here Are The 3 Best Stocks To Buy

BofA Downgrades Chemical Stocks Archer Daniels, Bunge

3 Fertilizer Stocks To Watch As Prices Go Parabolic

BofA Downgrades Chemical Stocks Archer Daniels, Bunge

3 Fertilizer Stocks To Watch As Prices Go Parabolic

BofA: 3 Upgrades, 3 Downgrades On New Set Of Global Challenges

5 Chemical Stocks Get Mixed Reaction: Which Ones Got An Upgrade Or Downgrade?

BofA: 3 Upgrades, 3 Downgrades On New Set Of Global Challenges

5 Chemical Stocks Get Mixed Reaction: Which Ones Got An Upgrade Or Downgrade?

BofA Raises Price Targets For Lithium Producers

BofA Upgrades Venator, Downgrades Celanese

Steve Byrne Recent News

Why This LyondellBasell Analyst Dropped Their Bearish Stance

Shares of LyondellBasell Industries NV (NYSE: LYB) have underperformed peers, despite a similar reduction in forecasts and offering a dividend that seems to be sustainable, according to BofA Securities.

Agricultural Chemical Companies Had A Good Start To 2020, And BofA Says It's Over

While agricultural chemicals companies reported significant volume growth in the first quarter, U.S.-centric suppliers have likely peaked, according to BofA Securities.

BofA Downgrades LyondellBasell, Dow, Says Polyethylene Producers Face Margin Pressure

The rebound in polyethylene is likely to be more challenging and companies like LyondellBasell Industries NV (NYSE: LYB) and The Dow Chemical Company (NYSE: DOW) could generate only modest earnings gains through 2021, accordi

BofA Turns Bearish On Livent After Bullish Conference Call

Bank Of America Upgrades CF Industries On Strong Q2, Improving 2020 Outlook

New DuPont 'Built For Success,' BofA Says In Bullish Initiation

BofA Downgrades Mosaic, Cites Phosphate Pricing Pressure

Mosaic Earns Double Upgrade On Sustainable Recovery In Phosphate

A Look Ahead At DowDuPont's Catalysts Over The Next Year; Analyst Initiates At Buy

Potash Corp Hit By Bank Of America Downgrade And Shares Are Falling

Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' Of Drug Approval

UPDATE: Bank Of America Reiterates On BioCryst Pharmaceuticals Following EU Physicians Survey

Bank Of America Q3 Small & Mid-Cap Biotech Preview

Bank Of America Sees Significant Manufacturing Capacity Expansions Underway For Pacira Pharmaceuticals

UPDATE: Bank Of America Downgrades Seattle Genetics, Inc. On Frontline Expectations

UPDATE: Bank Of America Reiterates On Vital Therapies On Improved Outlook

UPDATE: Bank Of America Downgrades Theravance As Pricing Headwinds Continue

UPDATE: Bank Of America Reiterates On Pacira Pharmaceuticals On Positive Survey Results

UPDATE: Bank Of America Reiterates On BioCryst Pharmaceuticals On Modestly Positive HAE Data

UPDATE: Bank of America Upgrades Seattle Genetics On Trial Risks

UPDATE: Bank of America Reiterates on Karyopharm Therapeutics on Significant Catalysts in 2014

UPDATE: Bank of America Reinstates Coverage on Incyte on Two Oncology Platforms

UPDATE: Bank of America Downgrades Vivus as Partnering Prospects Weaken